OA11432A - Recombinant rhabdovirus containing a heterologous fusion protein. - Google Patents
Recombinant rhabdovirus containing a heterologous fusion protein. Download PDFInfo
- Publication number
- OA11432A OA11432A OA1200000184A OA1200000184A OA11432A OA 11432 A OA11432 A OA 11432A OA 1200000184 A OA1200000184 A OA 1200000184A OA 1200000184 A OA1200000184 A OA 1200000184A OA 11432 A OA11432 A OA 11432A
- Authority
- OA
- OAPI
- Prior art keywords
- protein
- rhabdovirus
- cells
- recombinant
- vsv
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 40
- 102000037865 fusion proteins Human genes 0.000 title claims description 33
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 225
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 150
- 238000000034 method Methods 0.000 claims abstract description 58
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims abstract description 50
- 201000010099 disease Diseases 0.000 claims abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 15
- 210000004027 cell Anatomy 0.000 claims description 286
- 108091006027 G proteins Proteins 0.000 claims description 76
- 108091000058 GTP-Binding Proteins 0.000 claims description 76
- 208000015181 infectious disease Diseases 0.000 claims description 72
- 102000030782 GTP binding Human genes 0.000 claims description 69
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 46
- 229920001184 polypeptide Polymers 0.000 claims description 45
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 45
- 239000002299 complementary DNA Substances 0.000 claims description 35
- 230000004927 fusion Effects 0.000 claims description 30
- 239000012634 fragment Substances 0.000 claims description 27
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 17
- 210000000170 cell membrane Anatomy 0.000 claims description 17
- 210000004779 membrane envelope Anatomy 0.000 claims description 17
- 101710085938 Matrix protein Proteins 0.000 claims description 16
- 101710127721 Membrane protein Proteins 0.000 claims description 16
- 101710141454 Nucleoprotein Proteins 0.000 claims description 16
- 230000002159 abnormal effect Effects 0.000 claims description 15
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims description 14
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 claims description 13
- 101710181008 P protein Proteins 0.000 claims description 12
- 101710177166 Phosphoprotein Proteins 0.000 claims description 12
- 230000003612 virological effect Effects 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 7
- 244000045947 parasite Species 0.000 claims description 7
- 208000036142 Viral infection Diseases 0.000 claims description 6
- 210000005170 neoplastic cell Anatomy 0.000 claims description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
- 208000002741 leukoplakia Diseases 0.000 claims description 4
- 230000003071 parasitic effect Effects 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 208000030852 Parasitic disease Diseases 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 238000009007 Diagnostic Kit Methods 0.000 claims description 2
- 208000007256 Nevus Diseases 0.000 claims description 2
- POFWRMVFWIJXHP-UHFFFAOYSA-N n-benzyl-9-(oxan-2-yl)purin-6-amine Chemical compound C=1C=CC=CC=1CNC(C=1N=C2)=NC=NC=1N2C1CCCCO1 POFWRMVFWIJXHP-UHFFFAOYSA-N 0.000 claims description 2
- 230000001855 preneoplastic effect Effects 0.000 claims description 2
- SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 4
- 108010077805 Bacterial Proteins Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 4
- 239000003623 enhancer Substances 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 241000700605 Viruses Species 0.000 description 163
- 241000711975 Vesicular stomatitis virus Species 0.000 description 135
- 235000018102 proteins Nutrition 0.000 description 135
- 239000002245 particle Substances 0.000 description 42
- 241000711798 Rabies lyssavirus Species 0.000 description 32
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 31
- 239000013612 plasmid Substances 0.000 description 27
- 230000002458 infectious effect Effects 0.000 description 24
- 239000003795 chemical substances by application Substances 0.000 description 21
- 239000013598 vector Substances 0.000 description 21
- 239000005090 green fluorescent protein Substances 0.000 description 18
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 17
- 210000002845 virion Anatomy 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 16
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 15
- 101710091045 Envelope protein Proteins 0.000 description 15
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 15
- 101710188315 Protein X Proteins 0.000 description 15
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 14
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 14
- 241000700618 Vaccinia virus Species 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 14
- 102000005962 receptors Human genes 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 108020004635 Complementary DNA Proteins 0.000 description 11
- 239000002054 inoculum Substances 0.000 description 11
- 238000001415 gene therapy Methods 0.000 description 10
- 210000002443 helper t lymphocyte Anatomy 0.000 description 10
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 9
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 9
- 230000000120 cytopathologic effect Effects 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 230000010415 tropism Effects 0.000 description 7
- 102000003886 Glycoproteins Human genes 0.000 description 6
- 108090000288 Glycoproteins Proteins 0.000 description 6
- 101710137500 T7 RNA polymerase Proteins 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 238000010348 incorporation Methods 0.000 description 6
- 230000003362 replicative effect Effects 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 5
- 206010046865 Vaccinia virus infection Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000001086 cytosolic effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000012678 infectious agent Substances 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 208000007089 vaccinia Diseases 0.000 description 5
- 102000019034 Chemokines Human genes 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 4
- 241000699800 Cricetinae Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000013553 cell monolayer Substances 0.000 description 4
- 210000005220 cytoplasmic tail Anatomy 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 102000034287 fluorescent proteins Human genes 0.000 description 4
- 108091006047 fluorescent proteins Proteins 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 3
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 3
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 3
- 241001115402 Ebolavirus Species 0.000 description 3
- 101150082239 G gene Proteins 0.000 description 3
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 108010089430 Phosphoproteins Proteins 0.000 description 3
- 102000007982 Phosphoproteins Human genes 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 241000711931 Rhabdoviridae Species 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 101150057833 THEG gene Proteins 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000799 fluorescence microscopy Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000010820 immunofluorescence microscopy Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 241000701386 African swine fever virus Species 0.000 description 2
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 2
- 241000712892 Arenaviridae Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 2
- 241000711950 Filoviridae Species 0.000 description 2
- 241000710781 Flaviviridae Species 0.000 description 2
- 241000700739 Hepadnaviridae Species 0.000 description 2
- 101150062031 L gene Proteins 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 241000711828 Lyssavirus Species 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000711504 Paramyxoviridae Species 0.000 description 2
- 241000150350 Peribunyaviridae Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 241000712907 Retroviridae Species 0.000 description 2
- 241000711970 Vesiculovirus Species 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 231100001261 hazardous Toxicity 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940070376 protein Drugs 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000007501 viral attachment Effects 0.000 description 2
- 230000019540 viral envelope fusion with host membrane Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- YLDCUKJMEKGGFI-QCSRICIXSA-N 4-acetamidobenzoic acid;9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one;1-(dimethylamino)propan-2-ol Chemical compound CC(O)CN(C)C.CC(O)CN(C)C.CC(O)CN(C)C.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC=NC2=O)=C2N=C1 YLDCUKJMEKGGFI-QCSRICIXSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000724653 Borna disease virus Species 0.000 description 1
- 241000712462 Bovine ephemeral fever virus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 241000702749 Carajas virus Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000711969 Chandipura virus Species 0.000 description 1
- 241000288673 Chiroptera Species 0.000 description 1
- 241001185363 Chlamydiae Species 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 241000501789 Cocal virus Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 101100118548 Drosophila melanogaster Egfr gene Proteins 0.000 description 1
- 241001520695 Duvenhage lyssavirus Species 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 101100001677 Emericella variicolor andL gene Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 241000150562 Hantaan orthohantavirus Species 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 101900158831 Human immunodeficiency virus type 1 group M subtype B Envelope glycoprotein gp160 Proteins 0.000 description 1
- 101900082162 Human immunodeficiency virus type 1 group M subtype B Surface protein gp120 Proteins 0.000 description 1
- 241000711804 Infectious hematopoietic necrosis virus Species 0.000 description 1
- 241001109688 Isfahan virus Species 0.000 description 1
- 241001481498 Jurona vesiculovirus Species 0.000 description 1
- 241001331012 Kotonkan virus Species 0.000 description 1
- 241001520693 Lagos bat lyssavirus Species 0.000 description 1
- 206010023927 Lassa fever Diseases 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241001372913 Maraba virus Species 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000725171 Mokola lyssavirus Species 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101710195254 Non-structural glycoprotein Proteins 0.000 description 1
- 241000468053 Obodhiang virus Species 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 241000711965 Piry virus Species 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 241000223821 Plasmodium malariae Species 0.000 description 1
- 206010035501 Plasmodium malariae infection Diseases 0.000 description 1
- 241001505293 Plasmodium ovale Species 0.000 description 1
- 206010035502 Plasmodium ovale infection Diseases 0.000 description 1
- 241000223810 Plasmodium vivax Species 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 101710146873 Receptor-binding protein Proteins 0.000 description 1
- MJNIWUJSIGSWKK-UHFFFAOYSA-N Riboflavine 2',3',4',5'-tetrabutanoate Chemical compound CCCC(=O)OCC(OC(=O)CCC)C(OC(=O)CCC)C(OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-UHFFFAOYSA-N 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 108010059722 Viral Fusion Proteins Proteins 0.000 description 1
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 1
- 101150003160 X gene Proteins 0.000 description 1
- 241001481505 Yug Bogdanovac vesiculovirus Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000005101 cell tropism Effects 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- UMGXUWVIJIQANV-UHFFFAOYSA-M didecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC UMGXUWVIJIQANV-UHFFFAOYSA-M 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 102200016128 rs34631763 Human genes 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 101150115956 slc25a26 gene Proteins 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000005100 tissue tropism Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000010464 virion assembly Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20241—Use of virus, viral particle or viral elements as a vector
- C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6847297P | 1997-12-22 | 1997-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA11432A true OA11432A (en) | 2004-04-26 |
Family
ID=22082797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA1200000184A OA11432A (en) | 1997-12-22 | 2000-06-21 | Recombinant rhabdovirus containing a heterologous fusion protein. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US6497873B1 (enExample) |
| EP (1) | EP1040198B1 (enExample) |
| JP (1) | JP4544497B2 (enExample) |
| AP (1) | AP1968A (enExample) |
| AT (1) | ATE451466T1 (enExample) |
| AU (2) | AU752004B2 (enExample) |
| BR (1) | BR9814370A (enExample) |
| CA (1) | CA2316033A1 (enExample) |
| DE (1) | DE69841372D1 (enExample) |
| IL (2) | IL136905A0 (enExample) |
| MX (1) | MXPA00006184A (enExample) |
| NZ (1) | NZ505312A (enExample) |
| OA (1) | OA11432A (enExample) |
| WO (1) | WO1999032648A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2320239T3 (es) * | 1999-09-17 | 2009-05-20 | Wellstat Biologics Corporation | Virus oncolitico. |
| WO2002016437A2 (en) * | 2000-08-24 | 2002-02-28 | Thomas Jefferson University | Rhabdovirus-based vectors to express high levels of functional human antibodies |
| JP2004537279A (ja) * | 2001-03-09 | 2004-12-16 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 感染性ｃ型肝炎ウイルス合成のための細胞培養システム |
| US20030044386A1 (en) * | 2001-07-11 | 2003-03-06 | Barber Glen N. | Recombinant VSV for the treatment of tumor cells |
| US7820435B2 (en) * | 2002-02-06 | 2010-10-26 | Expression Technologies Inc. | De novo synthesized plasmid, methods of making and use thereof |
| ES2319424T3 (es) | 2003-03-27 | 2009-05-07 | Ottawa Health Research Institute | Virus mutantes de la estomatitis vesivular y sus usos. |
| US7731974B2 (en) | 2003-03-27 | 2010-06-08 | Ottawa Hospital Research Institute | Mutant vesicular stomatitis viruses and uses thereof |
| WO2005016961A1 (en) * | 2003-06-05 | 2005-02-24 | Wyeth Holdings Corporation | Immunogenic compositions comprising venezuelan equine encephalitis virus replicon vectors and paramyxovirus protein antigens |
| AU2004250129A1 (en) | 2003-06-09 | 2004-12-29 | Wyeth | Improved method for the recovery of non-segmented, negative-stranded RNA viruses from cDNA |
| EP2064229B1 (en) * | 2006-09-15 | 2015-08-12 | Ottawa Hospital Research Institute | Oncolytic rhabdovirus |
| WO2009014878A2 (en) * | 2007-07-06 | 2009-01-29 | Boyce Thompson Institute For Plant Research | Baculoviruses with enhanced virion production and a method for the production of baculoviruses |
| US8703469B2 (en) | 2007-07-06 | 2014-04-22 | Boyce Thompson Institute For Plant Research | Baculoviruses with enhanced virion production and a method for the production of baculoviruses |
| US20100215691A1 (en) * | 2009-02-20 | 2010-08-26 | Parks Christopher L | Recombinant viral vectors |
| AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
| EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
| US9347065B2 (en) | 2012-03-29 | 2016-05-24 | International Aids Vaccine Initiative | Methods to improve vector expression and genetic stability |
| WO2013158263A1 (en) | 2012-04-18 | 2013-10-24 | Mayo Foundation For Medical Education And Research | Replication-competent vesicular stomatitis viruses |
| FR2996856B1 (fr) * | 2012-10-15 | 2015-06-05 | Agronomique Inst Nat Rech | Novirhabdovirus recombinant utilisable comme vecteur d'antigenes |
| KR20200003160A (ko) * | 2017-05-03 | 2020-01-08 | 바이오마린 파머수티컬 인크. | 조혈모세포의 형질도입을 위한 개선된 렌티바이러스 |
| IL263979B2 (en) | 2017-05-10 | 2023-09-01 | Wellstat Immuno Therapeutics Llc | Viruses with an envelope resistant to the immune system for cancer treatment |
| JP2023513135A (ja) * | 2020-02-06 | 2023-03-30 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | 抗ラブドウイルス抗体を検出するのに有用なポリペプチド |
| WO2023051607A1 (zh) * | 2021-09-29 | 2023-04-06 | 上海行深生物科技有限公司 | 病毒培养方法 |
-
1998
- 1998-12-22 NZ NZ505312A patent/NZ505312A/xx unknown
- 1998-12-22 AT AT98963811T patent/ATE451466T1/de not_active IP Right Cessation
- 1998-12-22 JP JP2000525566A patent/JP4544497B2/ja not_active Expired - Fee Related
- 1998-12-22 AU AU19056/99A patent/AU752004B2/en not_active Ceased
- 1998-12-22 EP EP98963811A patent/EP1040198B1/en not_active Expired - Lifetime
- 1998-12-22 MX MXPA00006184A patent/MXPA00006184A/es not_active IP Right Cessation
- 1998-12-22 IL IL13690598A patent/IL136905A0/xx active IP Right Grant
- 1998-12-22 DE DE69841372T patent/DE69841372D1/de not_active Expired - Lifetime
- 1998-12-22 CA CA002316033A patent/CA2316033A1/en not_active Abandoned
- 1998-12-22 US US09/217,967 patent/US6497873B1/en not_active Expired - Fee Related
- 1998-12-22 WO PCT/US1998/026084 patent/WO1999032648A1/en not_active Ceased
- 1998-12-22 BR BR9814370-0A patent/BR9814370A/pt not_active Application Discontinuation
- 1998-12-22 AP APAP/P/2000/001852A patent/AP1968A/en active
-
2000
- 2000-06-20 IL IL136905A patent/IL136905A/en not_active IP Right Cessation
- 2000-06-21 OA OA1200000184A patent/OA11432A/en unknown
-
2002
- 2002-07-19 AU AU2002300207A patent/AU2002300207B2/en not_active Ceased
- 2002-10-23 US US10/277,997 patent/US20030138457A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2316033A1 (en) | 1999-07-01 |
| EP1040198B1 (en) | 2009-12-09 |
| AU1905699A (en) | 1999-07-12 |
| JP2001526901A (ja) | 2001-12-25 |
| AU752004B2 (en) | 2002-09-05 |
| AP1968A (en) | 2009-04-30 |
| WO1999032648A1 (en) | 1999-07-01 |
| AP2000001852A0 (en) | 2000-06-30 |
| US6497873B1 (en) | 2002-12-24 |
| NZ505312A (en) | 2003-01-31 |
| US20030138457A1 (en) | 2003-07-24 |
| MXPA00006184A (es) | 2003-02-11 |
| ATE451466T1 (de) | 2009-12-15 |
| DE69841372D1 (de) | 2010-01-21 |
| AU2002300207B2 (en) | 2006-07-13 |
| IL136905A (en) | 2007-10-31 |
| BR9814370A (pt) | 2000-10-10 |
| EP1040198A1 (en) | 2000-10-04 |
| JP4544497B2 (ja) | 2010-09-15 |
| IL136905A0 (en) | 2001-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU752004B2 (en) | Recombinant Rhabdovirus containing a heterologous fusion protein | |
| Robison et al. | The membrane-proximal stem region of vesicular stomatitis virus G protein confers efficient virus assembly | |
| Johnson et al. | Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins | |
| JP4434478B2 (ja) | リエンジニアリングされた外被を有するラブドウイルス | |
| Hu et al. | Functional interactions between the fusion protein and hemagglutinin-neuraminidase of human parainfluenza viruses | |
| Jeetendra et al. | The membrane-proximal domain of vesicular stomatitis virus G protein functions as a membrane fusion potentiator and can induce hemifusion | |
| Kretzschmar et al. | Membrane association of influenza virus matrix protein does not require specific hydrophobic domains or the viral glycoproteins | |
| US20050260601A1 (en) | Recombinant mutants of rhabdovirus and methods of use thereof | |
| Mebatsion et al. | Specific infection of CD4+ target cells by recombinant rabies virus pseudotypes carrying the HIV-1 envelope spike protein. | |
| Enkirch et al. | Targeted lentiviral vectors pseudotyped with the Tupaia paramyxovirus glycoproteins | |
| US20220025397A1 (en) | Ligand-directed targeting vectors | |
| US7041489B2 (en) | Recombinant respiratory syncytial viruses with deleted surface glycoprotein genes and uses thereof | |
| Schnell et al. | The application of reverse genetics technology in the study of rabies virus (RV) pathogenesis and for the development of novel RV vaccines | |
| US20240076690A1 (en) | Viral vectors and uses thereof | |
| Ma et al. | Murine leukemia virus pseudotypes of La Crosse and Hantaan Bunyaviruses: a system for analysis of cell tropism | |
| EP1549672A2 (en) | Ablated slam-dependent entry | |
| AU2006225325B2 (en) | Recombinant Rhabdovirus containing a heterologous fusion protein | |
| Roberts et al. | Redesign and genetic dissection of the rhabdoviruses | |
| US7994295B2 (en) | Recombinant viruses comprising the membrane-proximal domain of VSV G protein | |
| Grandi et al. | Targeting HSV amplicon vectors | |
| US20160101174A1 (en) | Lentiviral vectors with tropism to motor neurons comprising an antibody that binds to a pre-synaptic terminal receptor on the neuromuscular junction and a fusogenic protein | |
| Johnson | Assembly of foreign proteins into the envelope of vesicular stomatitis virus: Vaccine and targeting applications | |
| Costa et al. | Development of a 293T cell line for the production of virus like particles in bioreactors | |
| Eswaraka | Functional analysis of the membrane-proximal stem region of the vesicular stomatitis virus glycoprotein | |
| Omerovic | Functional characterization of Epstein-Barr virus gH/gL glycoprotein complex in fusion |